DOCK1抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04833(DOCK1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P04833(DOCK1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The DOCK1 antibody is a crucial tool for studying the Dedicator of Cytokinesis 1 (DOCK1) protein, a member of the DOCK-A subfamily within the DOCK family of guanine nucleotide exchange factors (GEFs). DOCK1. also known as DOCK180. primarily activates CDC42 and RAC1. Rho-family GTPases that regulate cytoskeletal dynamics, cell migration, and immune responses. It lacks the canonical Dbl homology domain but utilizes the DHR2 domain to catalyze GTP loading, enabling signal transduction pathways critical for cellular processes like phagocytosis, immune synapse formation, and neuronal development.

DOCK1 is highly expressed in immune cells (e.g., T cells, macrophages) and is implicated in pathological conditions, including cancer metastasis, inflammatory diseases, and neurological disorders. Its role in promoting cell invasion and metastasis makes it a potential therapeutic target in oncology.

The DOCK1 antibody is widely used in techniques such as Western blotting, immunofluorescence, and immunoprecipitation to analyze protein expression, localization, and interactions in both physiological and disease contexts. Researchers rely on its specificity to explore DOCK1’s mechanistic contributions to signaling networks and validate its association with disease progression. Validated antibodies are essential for distinguishing DOCK1 from homologous family members (e.g., DOCK2-5), ensuring accurate experimental outcomes in studies aiming to dissect its biological functions or therapeutic potential.